Joseph Schwartz
Stock Analyst at Leerink Partners
(4.94)
# 160
Out of 4,520 analysts
1310
Total ratings
53.9%
Success rate
32.4%
Average return
Main Sectors:
Stocks Rated by Joseph Schwartz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QNCX Quince Therapeutics | Initiated Coverage: Buy | $4 | $18.88 | -78.81% | 1 | Jun 24, 2026 | |
| QURE uniQure | Reiterated: Buy | $60 → $70 | $40.25 | +73.91% | 62 | Jun 17, 2026 | |
| EWTX Edgewise Therapeutics | Reiterated: Buy | $52 | $39.76 | +30.78% | 50 | Jun 16, 2026 | |
| CRNX Crinetics Pharmaceuticals | Maintained: Buy | $88 → $95 | $83.86 | +13.28% | 46 | Jun 11, 2026 | |
| ASND Ascendis Pharma | Reiterated: Buy | $225 → $305 | $261.00 | +16.86% | 72 | Jun 2, 2026 | |
| FULC Fulcrum Therapeutics | Downgraded: Hold | $24 → $4 | $3.65 | +9.59% | 37 | Jun 2, 2026 | |
| BMRN BioMarin Pharmaceutical | Reiterated: Hold | $60 → $62 | $59.59 | +4.04% | 90 | May 18, 2026 | |
| SPRB Spruce Biosciences | Reiterated: Buy | $160 → $120 | $43.54 | +175.61% | 32 | May 15, 2026 | |
| ANTX AN2 Therapeutics | Upgraded: Buy | $1 → $9 | $4.68 | +92.31% | 23 | May 15, 2026 | |
| RNA Atrium Therapeutics | Initiated Coverage: Buy | $25 | $12.15 | +105.76% | 1 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $28.10 | $12.29 | +128.64% | 1 | Apr 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $26 → $25 | $5.82 | +329.55% | 31 | Mar 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $15 | $17.22 | -12.89% | 107 | Mar 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $50 | $28.12 | +77.81% | 9 | Mar 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $6 | $0.1701 | +3,427.34% | 35 | Feb 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $56.71 | - | 87 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $29.28 | - | 69 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $38 | $34.94 | +8.76% | 37 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $1.86 | - | 50 | Dec 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 → $2 | $0.3101 | +544.95% | 31 | Dec 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 | $8.72 | +129.36% | 45 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $12 → $16 | $15.96 | +0.25% | 52 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $5 → $14 | $12.57 | +11.38% | 29 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $115 | $111.12 | +3.49% | 1 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $54 | $78.59 | -31.29% | 33 | Oct 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $108.32 | - | 63 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 | $3.70 | +575.68% | 22 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 | $2.25 | +344.44% | 29 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $1 | $0.733 | n/a | 29 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $10 | $4.20 | n/a | 19 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $14 | $224.35 | n/a | 1 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $150 → $30 | $8.26 | n/a | 10 | Aug 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $40 → $34 | $54.39 | n/a | 3 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 | $140.91 | n/a | 28 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $366.29 | n/a | 1 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $8.80 | n/a | 1 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $31 → $4 | $53.20 | n/a | 16 | Apr 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | n/a | $341.10 | n/a | 1 | May 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $53.39 | $240.97 | n/a | 1 | Apr 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $5 → $30 | $0.966 | n/a | 2 | Jan 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $37 → $23 | $11.38 | n/a | 2 | Nov 28, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 → $12 | $1.70 | n/a | 5 | Sep 26, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $121 → $126 | $535.67 | n/a | 4 | Apr 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $14.70 | n/a | 11 | Nov 13, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $0.06 | n/a | 5 | Nov 10, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 → $14 | $5.33 | n/a | 6 | Nov 10, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $24 | $0.7349 | n/a | 1 | Mar 8, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $664 | $676.69 | n/a | 7 | Oct 26, 2015 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $512 → $425 | $205.99 | n/a | 3 | Sep 15, 2015 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $20 → $8 | $80.18 | n/a | 3 | May 19, 2014 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $13.94 | n/a | 6 | Oct 30, 2013 |
Quince Therapeutics
Jun 24, 2026
Initiated Coverage: Buy
Price Target: $4
Current: $18.88
Upside: -78.81%
uniQure
Jun 17, 2026
Reiterated: Buy
Price Target: $60 → $70
Current: $40.25
Upside: +73.91%
Edgewise Therapeutics
Jun 16, 2026
Reiterated: Buy
Price Target: $52
Current: $39.76
Upside: +30.78%
Crinetics Pharmaceuticals
Jun 11, 2026
Maintained: Buy
Price Target: $88 → $95
Current: $83.86
Upside: +13.28%
Ascendis Pharma
Jun 2, 2026
Reiterated: Buy
Price Target: $225 → $305
Current: $261.00
Upside: +16.86%
Fulcrum Therapeutics
Jun 2, 2026
Downgraded: Hold
Price Target: $24 → $4
Current: $3.65
Upside: +9.59%
BioMarin Pharmaceutical
May 18, 2026
Reiterated: Hold
Price Target: $60 → $62
Current: $59.59
Upside: +4.04%
Spruce Biosciences
May 15, 2026
Reiterated: Buy
Price Target: $160 → $120
Current: $43.54
Upside: +175.61%
AN2 Therapeutics
May 15, 2026
Upgraded: Buy
Price Target: $1 → $9
Current: $4.68
Upside: +92.31%
Atrium Therapeutics
May 15, 2026
Initiated Coverage: Buy
Price Target: $25
Current: $12.15
Upside: +105.76%
Apr 6, 2026
Initiated Coverage: Buy
Price Target: $28.10
Current: $12.29
Upside: +128.64%
Mar 26, 2026
Reiterated: Buy
Price Target: $26 → $25
Current: $5.82
Upside: +329.55%
Mar 25, 2026
Maintained: Hold
Price Target: $15
Current: $17.22
Upside: -12.89%
Mar 25, 2026
Reiterated: Buy
Price Target: $50
Current: $28.12
Upside: +77.81%
Feb 23, 2026
Downgraded: Hold
Price Target: $6
Current: $0.1701
Upside: +3,427.34%
Jan 13, 2026
Maintained: Buy
Price Target: n/a
Current: $56.71
Upside: -
Jan 13, 2026
Reiterated: Buy
Price Target: n/a
Current: $29.28
Upside: -
Jan 13, 2026
Reiterated: Buy
Price Target: $38
Current: $34.94
Upside: +8.76%
Dec 31, 2025
Reiterated: Hold
Price Target: n/a
Current: $1.86
Upside: -
Dec 29, 2025
Reiterated: Buy
Price Target: $8 → $2
Current: $0.3101
Upside: +544.95%
Dec 15, 2025
Reiterated: Buy
Price Target: $20
Current: $8.72
Upside: +129.36%
Dec 3, 2025
Downgraded: Hold
Price Target: $12 → $16
Current: $15.96
Upside: +0.25%
Dec 3, 2025
Upgraded: Buy
Price Target: $5 → $14
Current: $12.57
Upside: +11.38%
Nov 10, 2025
Initiated Coverage: Buy
Price Target: $115
Current: $111.12
Upside: +3.49%
Oct 16, 2025
Reiterated: Hold
Price Target: $54
Current: $78.59
Upside: -31.29%
Sep 29, 2025
Reiterated: Buy
Price Target: n/a
Current: $108.32
Upside: -
Aug 15, 2025
Reiterated: Buy
Price Target: $25
Current: $3.70
Upside: +575.68%
Aug 7, 2025
Maintained: Buy
Price Target: $10
Current: $2.25
Upside: +344.44%
Aug 12, 2024
Reiterated: Hold
Price Target: $1
Current: $0.733
Upside: n/a
May 7, 2024
Reiterated: Hold
Price Target: $10
Current: $4.20
Upside: n/a
Sep 7, 2023
Maintained: Hold
Price Target: $14
Current: $224.35
Upside: n/a
Aug 18, 2023
Downgraded: Hold
Price Target: $150 → $30
Current: $8.26
Upside: n/a
Feb 3, 2023
Maintained: Hold
Price Target: $40 → $34
Current: $54.39
Upside: n/a
Aug 5, 2022
Reiterated: Buy
Price Target: $30
Current: $140.91
Upside: n/a
Aug 4, 2022
Rated: Hold
Price Target: n/a
Current: $366.29
Upside: n/a
Jul 13, 2022
Maintained: Buy
Price Target: n/a
Current: $8.80
Upside: n/a
Apr 5, 2022
Downgraded: Hold
Price Target: $31 → $4
Current: $53.20
Upside: n/a
May 7, 2021
Downgraded: Sell
Price Target: n/a
Current: $341.10
Upside: n/a
Apr 15, 2021
Maintained: Buy
Price Target: $53.39
Current: $240.97
Upside: n/a
Jan 6, 2021
Downgraded: Hold
Price Target: $5 → $30
Current: $0.966
Upside: n/a
Nov 28, 2018
Initiated Coverage: Buy
Price Target: $37 → $23
Current: $11.38
Upside: n/a
Sep 26, 2017
Maintained: Buy
Price Target: $10 → $12
Current: $1.70
Upside: n/a
Apr 3, 2017
Maintained: Hold
Price Target: $121 → $126
Current: $535.67
Upside: n/a
Nov 13, 2016
Reiterated: Buy
Price Target: n/a
Current: $14.70
Upside: n/a
Nov 10, 2016
Reiterated: Buy
Price Target: $8
Current: $0.06
Upside: n/a
Nov 10, 2016
Reiterated: Buy
Price Target: $12 → $14
Current: $5.33
Upside: n/a
Mar 8, 2016
Maintained: Buy
Price Target: $24
Current: $0.7349
Upside: n/a
Oct 26, 2015
Reiterated: Buy
Price Target: $664
Current: $676.69
Upside: n/a
Sep 15, 2015
Maintained: Buy
Price Target: $512 → $425
Current: $205.99
Upside: n/a
May 19, 2014
Initiated Coverage: Buy
Price Target: $20 → $8
Current: $80.18
Upside: n/a
Oct 30, 2013
Downgraded: Hold
Price Target: n/a
Current: $13.94
Upside: n/a